Respirodiagnostics

This company develops a non-invasive diagnostic platform that captures molecular signals from breath for early and accurate lung cancer detection. Their proprietary process provides high-resolution molecular data without requiring imaging or invasive procedures. The technology aims to create a scalable screening tool accessible in routine primary care settings.

Traction –/10

HQ unknown

Updated 4 months ago

Funding

Raised to date

£1MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Est. $1.3M

across 1 round

CXIUKL

£1M · Pre-Seed

Announced Jul 2026 · from article date

Disclosed cumulative: $1.3M

RoundDateAmountValuationInvestors

Founders

Founder details are not available yet.

Product

Features

This company develops a non-invasive diagnostic platform that analyzes molecular signals captured from a patient's breath for early cancer detection. Their proprietary process aims to provide high-resolution molecular data for more accurate screening than current imaging or invasive methods. The technology is designed to be scalable for use in primary care settings to improve access to early lung cancer detection.